G1 Therapeutics And Deimos Biosciences Announced A Global Licensing Agreement (Excluding The Asia-pacific Region) For Lerociclib For Radioprotective Uses; G1 Is Expected To Receive 10% Of Deimos Biosciences' Shares In Addition To A 20% Sales-based Royalty
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics and Deimos Biosciences have entered into a global licensing agreement (excluding the Asia-Pacific region) for Lerociclib for radioprotective uses. G1 Therapeutics will receive 10% of Deimos Biosciences' shares and a 20% sales-based royalty.
May 22, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
G1 Therapeutics has entered into a global licensing agreement with Deimos Biosciences for Lerociclib, excluding the Asia-Pacific region. G1 will receive 10% of Deimos' shares and a 20% sales-based royalty.
The licensing agreement is likely to positively impact G1 Therapeutics' stock price in the short term due to the potential revenue from the 20% sales-based royalty and the strategic benefit of holding 10% of Deimos Biosciences' shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100